Epidemiological and Pathophysiological Insights Through a Cross-sectional Survey (EPIC)

This study aims to better understand how mpox is spreading in the DRC, how it affects different groups of people, and how well vaccines protect against it. The study is designed as a cross-sectional survey, meaning researchers will collect and analyze data from patients diagnosed with mpox at a single point in time. It will also use a case-control approach, comparing people who test positive for the virus to those who test negative, to identify risk factors and evaluate the effectiveness of the vaccine.

NCT Number	NCT06840860
Lead Sponsor	Institute of Tropical Medicine, Belgium Collaborators: University of Manitoba, Catholic University of Bukavu, Democratic Republic of Congo, University of Bern, Alliance for International Medical Action, Institut de Recherche pour le Developpement, Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo, European and Developing Countries Clinical Trials Partnership (EDCTP), University of California, Los Angeles
Conditions	Monkeypox (Mpox)
Enrollment	1,000 participants
Start Date	2025-03-28
Primary Completion	2027-02-28 (estimated)
Study Completion	2027-02-28 (estimated)
Updated on ClinicalTrials.gov	2025-05-02